Therapeutic drug monitoring of mirtazapine, desmethylmirtazapine, 8-hydroxymirtazapine, and mirtazapine-N-oxide by enantioselective HPLC with fluorescence detection

Therapeutic Drug Monitoring

Volumn 28, Issue 6, 2006, Pages 760-765

  Meineke, Ingolf ^a   Steinmetz, Hannelore ^a   Kirchheiner, Julia ^b   Brockmöller, Jürgen ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Enantioselective HPLC; High performance liquid chromatography (HPLC); Mirtazapine; Pharmacokinetics

Indexed keywords

8 HYDROXYMIRTAZAPINE; DRUG METABOLITE; MIRTAZAPINE; MIRTAZAPINE N OXIDE; NORMIRTAZAPINE;

ACCURACY; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG URINE LEVEL; ENANTIOMER; ENANTIOSELECTIVITY; EXTRACTION; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOLATION PROCEDURE; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; URINALYSIS;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC N-OXIDES; DRUG MONITORING; FLUORESCENCE; HUMANS; MALE; MIANSERIN; QUALITY CONTROL; STEREOISOMERISM;

EID: 33845700634     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31802c0264     Document Type: Conference Paper

References (15)

1. Voortman G, Paanakker JE. Bioavailability of mirtazapine from remeron tablets after single and multiple oral dosing. Hum Psychopharmacol. 1995;10:S83-S96.
2. Timmer CJ, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38:461-474.
3. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(Suppl 4):19-25.
4. Delbressine LPC, Moonen FM, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine. Clin Drug Invest. 1998;15:45-55.
5. Kirchheiner J, Henckel HB, Meineke I, et al. Impact of the CYP2D6 ultra rapid genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004;24:647-652.
6. Dahl ML, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest. 1997;13:37-46.
7. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143:415-426.
8. Maris FA, Dingler E, Niehues S. High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its desmethyl metabolite in human plasma. J Chromatogr. 1999;721:309-316.
9. Romiguieres T, Pehourq F, Matoga M, et al. Determination of mirtazapine and its desmethyl metabolite in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 2002;775:163-168.
10. Ptacek P, Klima J, Macek J. Determination of mirtazapine in human plasma by liquid chromatography. J Chromatogr. 2003;794:323-328.
11. Morgan PE, Tapper J, Spencer EP. Measurement of total mirtazapine and normirtazapine in plasma/serum by liquid chromatography with fluorescence detection. J Chromatogr. 2003;798:211-215.
12. Meineke I, Kress I, Poser W, et al. Therapeutic drug monitoring of mirtazapine and its metabolite desmethyl mirtazapine by HPLC with fluorescence detection. Ther Drug Monit. 2004;26:277-283.
13. Dodd S, Burrows GD, Norman TR. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr. 2000;748:439-443.
14. Paus E, Jonzier-Perey M, Cochard N, et al. Chirality in the new generation of antidepressants. Ther Drug Monit. 2004;26:366-374.
15. Engelhardt S, Meineke I, Brockmöller J. Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. J Chromatogr B. 2006;831:31-35.